Four ‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

British Journal of Haematology, EarlyView.

Source: British Journal of Haematology - May 22, 2018 Category: Hematology Authors: Preetesh Jain , Jorge Romaguera , Samer A. Srour , Hun J. Lee , Frederick Hagemeister , Jason Westin , Luis Fayad , Felipe Samaniego , Maria Badillo , Liang Zhang , Lorreta Nastoupil , Rashmi Kanagal ‐Shamanna , Nathan Fowler , Source Type: research